← ANALYST RATINGS · TIPRANKS
Icon (ICLR): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy5 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $188, the highest $220, the lowest $165. The average is +10.6% from the last price of $170.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $185 | Buy | +8.7% | Reiterated | 12.10.26on TipRanks 07:45 | +0.2%next day 0.0% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Hold | — | Upgrade | 09.10.26on TipRanks 07:55 | −0.8%next day +0.2% · 5 days +5.6% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $175 | Hold | +2.8% | Reiterated | 07.10.26on TipRanks 04:00 | +1.7%next day +0.7% · 5 days +4.0% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $220 → $195−11.4% | Hold | +14.6% | Initiated | 30.09.26on TipRanks 05:40 | 0.0%next day −5.0% · 5 days −5.4% | ↗ |
| Name not given | — | $180 → $175−2.8% | Hold | +2.8% | Reiterated | 18.09.26on TipRanks 06:50 | −3.4%next day +1.8% · 5 days +3.7% | ↗ |
| Jailendra Singh★★★★★★★★★★#12131 · hits 43% · avg −6.4% | Truist Financial | — | Buy | — | Reiterated | 17.09.26on TipRanks 08:09 | −3.6%next day −3.4% · 5 days +1.6% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $181 → $183+1.1% | Hold | +7.5% | Reiterated | 28.08.26on TipRanks Aug 27 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $188 → $186−1.1% | Buy | +9.3% | Reiterated | 28.08.26on TipRanks Aug 27 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $181 → $187+3.3% | Buy | +9.9% | Upgrade | 28.08.26on TipRanks Aug 27 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $170 → $174+2.4% | Hold | +2.2% | Reiterated | 28.08.26on TipRanks Aug 27 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $180 → $188+4.4% | Buy | +10.5% | Upgrade | 28.08.26on TipRanks Aug 27 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $185 → $189+2.2% | Buy | +11.1% | Reiterated | 28.08.26on TipRanks Aug 27 23:05 | — | |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $155 → $165+6.5% | Hold | −3.0% | Reiterated | 04.08.26on TipRanks Aug 5 08:08 | −2.8%next day +4.4% · 5 days +5.7% | ↗ |
| Charles Rhyee★★★★★★★★★★#1937 · hits 54% · avg +5.6% | TD Cowen | $197 | Buy | +15.8% | Assigned | 03.08.26on TipRanks 04:30 | −4.6%next day −2.8% · 5 days +2.8% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $192 → $194+1.0% | Buy | +14.0% | Reiterated | 31.07.26on TipRanks 07:35 | −1.9%next day −4.6% · 5 days −2.9% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $220 | Buy | +29.3% | Reiterated | 30.07.26on TipRanks 11:45 | −8.8%next day −1.9% · 5 days −6.3% | ↗ |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Buy | — | Reiterated | 29.07.26on TipRanks 18:55 | −8.8%next day −1.9% · 5 days −6.3% | ↗ |
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $180 → $190+5.6% | Buy | +11.6% | Reiterated | 26.06.26on TipRanks 07:18 | +6.3%next day +0.2% · 5 days −2.4% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $180 → $188+4.4% | Buy | +10.5% | Reiterated | 25.06.26on TipRanks 09:31 | +1.6%next day +6.3% · 5 days +6.1% | ↗ |
| David Windley★★★★★★★★★★#769 · hits 59% · avg +9.3% | Jefferies | $135 → $193+43.0% | Buy | +13.4% | Reiterated | 25.06.26on TipRanks 08:30 | +1.6%next day +6.3% · 5 days +6.1% | ↗ |
| Sean Dodge★★★★★★★★★★#11980 · hits 43% · avg −4.3% | BMO Capital | $160 → $187+16.9% | Buy | +9.9% | Reiterated | 25.06.26on TipRanks 08:08 | +1.6%next day +6.3% · 5 days +6.1% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | $125 → $145+16.0% | Hold | −14.8% | Reiterated | 28.05.26on TipRanks 13:35 | +14.9%next day −0.8% · 5 days +11.4% | ↗ |
| Jamie Clark★★★★★★★★★★#6680 · hits 75% · avg +5.9% | Rothschild & Co Redburn | $226 → $100−55.8% | Hold | −41.2% | Downgrade | 17.02.26on TipRanks 05:10 | −4.9%next day +8.4% · 5 days +16.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Icon
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $186 at a price of $170 (+9.6%); now: $188 at $170 (+10.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 8 | 16 | 21 | 16 | 8 | 4 |
| Hold | 13 | 15 | 14 | 6 | 3 | 5 |
| Sell | 1 | 3 | 4 | 3 | 1 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.63 (from $2.56 to $2.75). Last quarter: $2.56.
Sales
Next quarter’s sales estimate — $2.0B (from $2.0B to $2.0B). Last quarter: $2.1B.
Best top-analyst consensus in the sector · Healthcare
About Icon
- CEO: Barry Balfe
- Employees: 40,200
- South County Business Park, Dublin, DU, D18 X5R3, IE
- www.iconplc.com
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Data from the stock’s TipRanks forecast page, read 66 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗